Skip to main content

Drug Interactions between efavirenz and st. john's wort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

efavirenz St. John's wort

Applies to: efavirenz and st. john's wort

GENERALLY AVOID: Coadministration with St. John's wort may significantly reduce the plasma concentrations of certain antiretroviral agents such as nonnucleoside reverse transcriptase inhibitors (NNRTIs), and CCR5 coreceptor antagonists. The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John's wort. In eight healthy volunteers, St. John's wort (300 mg, standardized to 0.3% hypericin, three times a day for 14 days) decreased the 8-hour area under the plasma concentration-time curve (AUC) and extrapolated 8-hour trough of indinavir (800 mg every 8 hours for 4 doses) by a mean of 57% and 81%, respectively, compared to administration of indinavir alone. All participants showed a reduction in the indinavir 8-hour postdose concentration ranging from 49% to 99%. The interaction was also suspected as the cause of low nevirapine plasma levels in five HIV patients who used St. John's wort while being treated with nevirapine and two nucleoside reverse transcriptase inhibitors.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, patients treated with antiretroviral agents should avoid using St. John's wort. Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.

References (21)
  1. (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
  2. (2001) "Product Information. Crixivan (indinavir)." Merck & Co., Inc
  3. (2001) "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc
  4. (2001) "Product Information. Agenerase (amprenavir)." Glaxo Wellcome
  5. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV (1999) "Indinavir concentrations and antiviral effect." Pharmacotherapy, 19, p. 708-12
  6. FDA (2001) FDA public health advisory on risk of drug interactions with St John's wort and indinavir and other drugs. URL: http://www.fda.gov/cder/drug/advisory/sjwort.htm
  7. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) "Indinavir concentrations and St John's wort." Lancet, 355, p. 547-8
  8. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) "St John's Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther, 67, p. 451-7
  9. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P (2000) "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids, 14, p. 1333-9
  10. (2001) "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical
  11. (2001) "Product Information. Fortovase (saquinavir)." Roche Laboratories
  12. de Maat MM, Hoetelmans RM, Mathot RA, et al. (2001) "Drug interaction between St John's wort and nevirapine." AIDS, 15, p. 420-1
  13. Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) "St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther, 68, p. 598-604
  14. Veldkamp AI, Weverling GJ, Lange JM, et al. (2001) "High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals." AIDS, 15, p. 1089-95
  15. Mangum EM, Graham KK (2001) "Lopinavir-Ritonavir: a new protease inhibitor." Pharmacotherapy, 21, p. 1352-63
  16. Izzo AA, Ernst E (2001) "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs, 61, p. 2163-75
  17. (2003) "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb
  18. (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline
  19. (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
  20. (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc
  21. (2007) "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group

Drug and food interactions

Moderate

efavirenz food

Applies to: efavirenz

ADJUST DOSING INTERVAL: Administration with food increases the plasma concentrations of efavirenz and may increase the frequency of adverse reactions. According to the product labeling, administration of efavirenz capsules (600 mg single dose) with a high-fat/high-caloric meal (894 kcal, 54 g fat, 54% calories from fat) or a reduced-fat/normal-caloric meal (440 kcal, 2 g fat, 4% calories from fat) was associated with mean increases of 39% and 51% in efavirenz peak plasma concentration (Cmax) and 22% and 17% in systemic exposure (AUC), respectively, compared to administration under fasted conditions. For efavirenz tablets, administration of a single 600 mg dose with a high-fat/high-caloric meal (approximately 1000 kcal, 500-600 kcal from fat) resulted in a 79% increase in mean Cmax and a 28% increase in mean AUC of efavirenz relative to administration under fasted conditions.

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of efavirenz. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

MANAGEMENT: Efavirenz should be taken on an empty stomach, preferably at bedtime. Dosing at bedtime may improve the tolerability of nervous system symptoms such as dizziness, insomnia, impaired concentration, somnolence, abnormal dreams and hallucinations, although they often resolve on their own after the first 2 to 4 weeks of therapy . Patients should be advised of the potential for additive central nervous system effects when efavirenz is used concomitantly with alcohol or psychoactive drugs, and to avoid driving or operating hazardous machinery until they know how the medication affects them.

References (4)
  1. (2001) "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals
  2. (2023) "Product Information. Sustiva (efavirenz)." Bristol-Myers Squibb, SUPPL-59/47
  3. (2024) "Product Information. Stocrin (efavirenz)." Merck Sharp & Dohme (Australia) Pty Ltd
  4. (2024) "Product Information. Efavirenz (efavirenz)." Viatris UK Healthcare Ltd
Moderate

St. John's wort food

Applies to: st. john's wort

GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.

References (1)
  1. Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.